Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
| Net income | -$7.06M | -$12.0M | -$7.85M | -$10.4M |
| EPS (diluted) | -$0.40 | -$0.85 | -$0.51 | -$1.35 |
| Fiscal year | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
| Operating cash flow | -$5.60M | -$4.53M | -$5.56M | -$4.66M |
| Fiscal year | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
| Cash & equivalents | — | — | $2.83M | $6.35M |
| Total assets | $858K | $4.93M | $2.92M | $11.1M |
| Total liabilities | $1.45M | $558K | $723K | $702K |
| Shareholders' equity | -$596K | $4.37M | $2.20M | $10.4M |
| Retained earnings | -$9.30M | -$21.3M | -$29.1M | -$39.6M |
| Shares (wtd avg diluted) | 17.6M | 13.9M | 15.4M | 23.7M |
Every figure is extracted from MIRA PHARMACEUTICALS, INC.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.